Table 4 Quantification of myeloid and lymphoid cells in controls and CF, with male and female subdivision

Control subjects

Male CF patients

Female CF patients

ANOVA

Neutrophils (MPO)

17.4 (7.1–30.5)

30.1 (25.4–45.5)

36.3 (24.0–51.8)*

0.0009

Eosinophils (EG-2)

1.0 (0.4–2.9)

0.3 (0.1–2.3)

4.7 (1.8–9.6)^§§

0.004

Mast cells (tryptase)

10.5 (8.8–14.4)

12.5 (7.9–16.5)

23.0 (18.7–32.3)***^{, §§}

0.0005

Dendritic cells (CD1a)

0.8 (0.4–1.5)

2.2 (1.5–3.9)*

3.6 (2.7–6.6)***

<0.0001

Dendritic cells (CD207)

1.0 (0.3–1.8)

4.3 (3.3–8.0)***

5.2 (2.8–14.3)***

<0.0001

Macrophages (CD163)

18.7 (10.3–25.1)

33.5 (23.2–43.2)**

26.9 (16.7–40.5)

0.0058

CD4 T cells

3.8 (0.6–7.6)

2.9 (1.2–7.1)

21.7 (10.8–29.8)***^{, §§}

<0.0001

Cytotoxic T cells (CD8)

1.5 (0.2–11.4)

23.7 (12.7–58.6)*

71.5 (48.1–115.0)***

<0.0001

B cells (CD20)

0.0 (0.0–0.9)

0.5 (0.0–1.3)

0.3 (0.1–0.6)

0.21

Lymphoid follicles

0.0 (0.0–0.009)

0.04 (0.01–0.1)***

0.065 (0.028–0.071)***

<0.0001